Fostamatinib Disodium Hexahydrate Tablet to Be Dispensed by US Bioservices for ITP
Rare Disease Report
Rigel Pharmaceuticals has recently selected US Bioservices to dispense fostamatinib disodium hexahydrate (TAVALISSE) tablets, for the treatment of adult patients with chronic immune thrombocytopenia (ITP), a rare blood disorder, who have had an insufficient response to a previous treatment. Fostamatinib disodium hexahydrate was approved by the US Food and Drug Administration (FDA) on April 17, 2018, for the treatment of adult patients with chronic ITP.
For the full article, visit Rare Disease Report.